PHARMACOKINETICS AND SAFETY OF CT-P47, A PROPOSED TOCILIZUMAB BIOSIMILAR, IN COMPARISON WITH EU-APPROVED TOCILIZUMAB; A PHASE 1, RANDOMIZED, DOUBLE-BLIND, TWO-ARM, SINGLE-DOSE STUDY IN HEALTHY SUBJECTS.

Authors :: Yu, K. S.
Kim, B.
Shin, D.
Park, M. K.
Hwang, J. G.
Kim, M.
Chung, H.
Ghim, J.
Chung, J. Y.
Smolen, J. S.
Burmester, G. R.
Kim, S. H.
Bae, Y.
Jeon, D.
Yang, G.
Yoo, J.
Bae, J.
Keystone, E.
Source :: Annals of the Rheumatic Diseases; 2023 Supplement, Vol. 82, p1385-1386, 2p
Publication Year :: 2023

Full Text Access

Tools